Background. Present day in medicine can be assessed as an active period of the fight against cardiovascular diseases. This group of diseases cannot be considered obsolete in any way, and even taking into account the emerging new pathology – coronavirus infection – cardiovascular diseases have consolidated their dominant position. Among the drugs used for appropriate pharmacotherapy, stands out nifedipine (1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridindicarboxylic acid dimethyl ether) – a drug that can inhibit the flow of calcium into the cardiomyocytes of vascular smooth muscle cells. The drug has been on the domestic pharmaceutical market for quite a long time, but it is still in demand. However, nifedipine has quite pronounced side effects, including those associated with its oral administration – nausea caused by irritation of the gastrointestinal tract, rarely gum hyperplasia. And at the same time, the main modern dosage form of nifedipine is tablets. Therefore, expanding the range of its dosage forms is an urgent issue. Moreover, well-chosen dosage forms reduce the side effect of the drug. This is especially true for extended versions. So pharmaceutical development in relation to the creation of original dosage forms of nifedipine is quite appropriate.Aim. Determination of the possibility of absorption of nifedipine from the proposed dosage forms – transdermal patch and transdermal gel.Materials and methods. To determine nifedipine in rat blood plasma samples, high-performance liquid chromatography was used (chromatograph “Millichrome A-02” (Institute of Chromatography “EcoNova”, LLC, Russia).Results. Chromatograms of blood plasma samples of all animals on whose skin a transdermal gel or patch was applied revealed a peak coinciding in retention time with the peak of the standard sample of nifedipine.Conclusion. The possibility of penetration of nifedipine from the patch and transdermal gel through intact animal skin has been confirmed.

No abstract

No abstract

No abstract